Mesothelioma

Mesothelioma Overview
Disease Type	Aggressive Cancer of the Mesothelium
Primary Cause	Asbestos Exposure (~80% of cases)
Annual U.S. Incidence	~3,000 new cases per year
5-Year Survival Rate	~10% (all types/stages combined)
Latency Period	20–50 years (median 44.6 years)
Types	Pleural (81%), Peritoneal (11%), Pericardial (<1%), Testicular (<1%)
Trust Fund Compensation	$30+ billion across 60+ active trusts
Average Settlement	$1 million–$1.4 million
📞 Free Case Review →

Mesothelioma: ~3,000 Annual U.S. Diagnoses, 20–50 Year Latency, $30+ Billion in Compensation Available

Mesothelioma is a rare and aggressive form of cancer that develops in the mesothelium — the thin layer of tissue lining the lungs, abdomen, heart, and other internal organs. Approximately 80% of all mesothelioma cases are directly linked to occupational or environmental asbestos exposure. The disease is characterized by an exceptionally long latency period of 20 to 50 years between initial asbestos exposure and diagnosis, meaning individuals exposed decades ago continue to be diagnosed today. According to CDC data, 2,669 new cases were reported in the United States in 2022, with the American Cancer Society estimating approximately 3,000 new diagnoses annually. Mesothelioma patients and their families may be entitled to significant compensation through asbestos trust funds, lawsuits, VA benefits, and other legal pathways — with more than $30 billion currently available in active trust funds nationwide.

Despite decades of medical research, mesothelioma remains one of the most difficult cancers to treat due to its late-stage diagnosis patterns and resistance to conventional therapies. The disease disproportionately affects military veterans — who represent approximately 30% of all diagnoses — along with construction workers, shipyard employees, industrial tradespeople, and their families through secondary household exposure. This page provides a comprehensive overview of mesothelioma's causes, symptoms, diagnostic process, treatment options, and the full range of legal compensation pathways available to patients and their families. For immediate guidance after a diagnosis, see Emergency Action Checklist and Understanding Your Diagnosis.

📋 Key Facts About Mesothelioma

Annual U.S. diagnoses: ~3,000 new cases per year (2,669 reported in 2022 per CDC) Global incidence: Estimated 30,000–40,000 cases annually worldwide Primary cause: Asbestos exposure accounts for approximately 80% of all cases Median age at diagnosis: 72–75 years depending on the data source Male-to-female ratio: Approximately 3:1 to 4:1, reflecting historical occupational exposure patterns Latency period: 20–50 years from exposure to diagnosis (median 44.6 years per Italian ReNaM registry data) 5-year survival rate: ~10% overall; 65% for peritoneal mesothelioma, 12% for pleural mesothelioma Histological types: Epithelioid (50–70%), biphasic (20–35%), sarcomatoid (10–20%) Trust fund compensation: $30+ billion available across 60+ active asbestos bankruptcy trusts Average settlement: $1 million–$1.4 million; average trial verdict: $20.7 million (2024 data) Veterans: Account for approximately 30% of all mesothelioma diagnoses despite being ~7% of the population FDA-approved treatments: Three systemic regimens approved since 2004, including immunotherapy (2020, 2024)

What Is Mesothelioma?

Mesothelioma is a malignant tumor that arises from the mesothelial cells lining the body's serous cavities. Unlike lung cancer, which develops within the lung tissue itself, mesothelioma originates in the protective membrane surrounding organs — a critical distinction that affects diagnosis, staging, treatment, and prognosis. The disease is classified into four anatomical types based on where the cancer develops:

Pleural mesothelioma accounts for approximately 81% of all cases and develops in the pleura, the membrane surrounding the lungs. It is the most studied and best-understood form of the disease. Peritoneal mesothelioma represents approximately 11% of cases and arises in the peritoneum, the lining of the abdominal cavity. Peritoneal patients generally have better outcomes, with a 5-year survival rate of approximately 65% when treated with cytoreductive surgery and heated intraperitoneal chemotherapy (HIPEC). Pericardial mesothelioma (<1% of cases) develops in the pericardium surrounding the heart, and testicular mesothelioma (<1% of cases) originates in the tunica vaginalis. Both are exceptionally rare.

Mesothelioma is further classified by cell type, which significantly influences treatment response and prognosis. Epithelioid mesothelioma (50–70% of cases) carries the best prognosis, with a median overall survival of 22.2 months. Biphasic mesothelioma (20–35% of cases) contains both epithelioid and sarcomatoid cells, with a median survival of 12.4 months. Sarcomatoid mesothelioma (10–20% of cases) is the most aggressive subtype, with a median survival of just 6.4 months. For a detailed comparison, see Mesothelioma Types.

"Mesothelioma is one of the most misunderstood cancers. Many families we work with had never heard of it before their diagnosis. Understanding the disease — its causes, its timeline, and the legal options available — is the critical first step toward getting the help you deserve."

— Paul Danziger, Esq., Founding Partner, Danziger & De Llano

What Causes Mesothelioma?

Asbestos exposure is the established primary cause of mesothelioma, responsible for approximately 80% of all diagnosed cases worldwide. Asbestos is a group of six naturally occurring fibrous minerals — chrysotile, crocidolite, amosite, tremolite, actinolite, and anthophyllite — that were used extensively in construction, shipbuilding, manufacturing, and automotive industries throughout the 20th century.

When asbestos-containing materials are disturbed, microscopic fibers become airborne and can be inhaled or ingested. These fibers embed in the mesothelial tissue lining the lungs, abdomen, or other organs, causing chronic inflammation, cellular DNA damage, and eventually malignant transformation over a period of decades. The disease develops through three primary exposure pathways:

Occupational exposure is the most common pathway and accounts for the majority of mesothelioma cases. Workers in construction, shipbuilding, insulation installation, power generation, chemical manufacturing, steel production, and automotive repair face the highest risk. According to occupational health data, insulation workers face among the highest mortality rates — up to 46 times the expected rate in the general population.

Secondary exposure (also called take-home or paraoccupational exposure) occurs when asbestos fibers are carried home on workers' clothing, hair, or skin, exposing family members — predominantly spouses and children — to dangerous levels of the mineral. For detailed information, see Secondary Exposure.

Environmental exposure occurs in communities near naturally occurring asbestos deposits or contaminated industrial sites. Notable examples include Libby, Montana, where vermiculite mining operations contaminated the town, and Stratford, Connecticut.

In March 2024, the EPA finalized a rule banning ongoing uses of chrysotile asbestos in the United States under the Toxic Substances Control Act (TSCA), with a phased implementation timeline extending through 2036 for certain industrial uses. The ban's enforcement was upheld following a period of legal uncertainty in mid-2025.

Non-asbestos causes of mesothelioma are rare but documented. Erionite, a naturally occurring fibrous zeolite mineral found in parts of Turkey, has been linked to mesothelioma clusters. Prior radiation therapy and genetic susceptibility (particularly BAP1 gene mutations) are also recognized risk factors.

What Are the Symptoms of Mesothelioma?

Mesothelioma symptoms vary depending on the anatomical type and often mimic more common, less serious conditions — a key reason why the disease is frequently misdiagnosed or diagnosed at an advanced stage. Research indicates that approximately 37% of patients cite misdiagnosis or vague symptoms as the primary barrier to timely diagnosis, with diagnostic delays averaging 6 months or longer from initial symptom onset.

Pleural mesothelioma symptoms include persistent chest pain or pressure, shortness of breath (dyspnea), chronic dry cough, pleural effusion (fluid buildup around the lungs), unexplained weight loss, and fatigue. These symptoms frequently lead to initial misdiagnoses of pneumonia, chronic obstructive pulmonary disease (COPD), or other respiratory conditions.

Peritoneal mesothelioma symptoms include abdominal pain or swelling, ascites (fluid accumulation in the abdomen), nausea, changes in bowel habits, and unexplained weight loss. Peritoneal mesothelioma is most commonly mistaken for ovarian cancer in women, irritable bowel syndrome (IBS), or other gastrointestinal conditions.

Pericardial mesothelioma symptoms include chest pain, heart palpitations, difficulty breathing, and pericardial effusion. These symptoms often lead to initial cardiac diagnoses before the underlying malignancy is identified.

Anyone with a history of asbestos exposure who experiences these symptoms should inform their physician of their exposure history, as awareness of prior asbestos contact significantly shortens the diagnostic timeline. See Understanding Your Diagnosis and Emergency Action Checklist for immediate steps after a suspected or confirmed diagnosis.

How Is Mesothelioma Diagnosed?

Diagnosing mesothelioma is a multi-step process that typically begins when imaging studies reveal abnormalities such as pleural thickening, pleural effusion, or peritoneal masses. The diagnostic pathway generally progresses through three stages:

Imaging studies form the first step. A chest X-ray may reveal pleural effusion or thickening, prompting further investigation with computed tomography (CT) scans, which provide detailed cross-sectional images. PET (positron emission tomography) scans help determine the extent of metabolically active disease and aid in staging.

Tissue biopsy is required for definitive diagnosis. Depending on the suspected type, this may involve thoracoscopy (video-assisted thoracic surgery, or VATS) for pleural cases, laparoscopy for peritoneal cases, or CT-guided needle biopsy. Fluid cytology from pleural or peritoneal effusions may suggest mesothelioma but is generally considered insufficient for a definitive diagnosis on its own.

Pathological confirmation through immunohistochemistry (IHC) is essential because epithelioid mesothelioma closely resembles adenocarcinoma under standard microscopy. A 2023 study in the Journal of Thoracic Oncology found that 14% of mesothelioma diagnoses in well-resourced pathology settings were incorrect, with misdiagnosis rates approaching 50% in resource-limited settings. This makes review by a pathologist with mesothelioma experience critically important.

Emerging diagnostic biomarkers include soluble mesothelin-related peptide (SMRP/MESOMARK), fibulin-3, and osteopontin, though no blood-based screening test has yet been approved for routine clinical use. Research into BAP1 immunohistochemistry and liquid biopsy techniques continues to advance, with potential to improve early detection in the future. See Medical Terms Glossary for explanations of diagnostic terminology.

What Are the Stages of Mesothelioma?

Pleural mesothelioma is staged using the TNM (Tumor, Nodes, Metastasis) system, which classifies the disease into four stages based on tumor extent, lymph node involvement, and distant spread.

Stage	Description	Median Survival	5-Year Survival
Stage I	Localized to one side of the pleura; best candidates for surgery	21+ months	18–20%
Stage II	Spread to nearby lymph nodes or diaphragm	~19 months	~12%
Stage III	Spread to chest wall, mediastinum, or distant lymph nodes	~16 months	~14%
Stage IV	Metastatic spread to distant organs	~12 months	~9%

Peritoneal mesothelioma does not have a standardized staging system. Instead, clinicians use the Peritoneal Cancer Index (PCI), which scores tumor burden across 13 abdominal regions on a scale of 0 to 39. Lower PCI scores generally indicate better surgical candidacy and improved outcomes. See Survival Statistics for comprehensive survival data by type and stage.

Earlier detection significantly expands treatment options. Stage I and II patients may qualify for surgical intervention, while advanced-stage patients typically rely on systemic therapies. This underscores the importance of seeking prompt medical evaluation when symptoms arise, especially for individuals with known asbestos exposure history.

What Treatment Options Are Available for Mesothelioma?

Mesothelioma treatment has advanced significantly in recent years, with three FDA-approved systemic regimens and several emerging therapies now available. The current standard of care depends on disease stage, histological subtype, and patient fitness.

Surgery

Pleurectomy/decortication (P/D) is the preferred surgical approach for operable pleural mesothelioma, removing the diseased pleural lining while preserving the underlying lung. The 2025 NCCN Guidelines recommend P/D over the more aggressive extrapleural pneumonectomy (EPP), which removes the entire affected lung, and restrict surgical candidacy to early-stage (stage I) epithelioid cases with no lymph node involvement.

For peritoneal mesothelioma, cytoreductive surgery (CRS) combined with heated intraperitoneal chemotherapy (HIPEC) remains the gold-standard treatment, producing 5-year survival rates of approximately 65% in appropriately selected patients.

Chemotherapy

The first-line chemotherapy regimen for mesothelioma is pemetrexed combined with cisplatin or carboplatin, originally approved in 2004. This combination remains the standard chemotherapy backbone for epithelioid mesothelioma and is frequently combined with immunotherapy agents in current practice.

Immunotherapy

Nivolumab plus ipilimumab (CheckMate 743 trial) was approved by the FDA in October 2020 as the first immunotherapy regimen for unresectable malignant pleural mesothelioma. Long-term follow-up data show 4-year overall survival rates of 16.8% versus 10.7% for chemotherapy alone, with the benefit most pronounced in non-epithelioid (sarcomatoid/biphasic) subtypes where median survival nearly doubled.

In September 2024, the FDA approved pembrolizumab (Keytruda) combined with pemetrexed and platinum chemotherapy (KEYNOTE-483 trial) as a second immunotherapy-based first-line option, achieving 3-year overall survival rates of 25% compared to 17% with chemotherapy alone.

Emerging Therapies

Tumor Treating Fields (TTFields/Optune Lua) received FDA approval through the Humanitarian Device Exemption pathway for use with chemotherapy in first-line MPM, achieving a median overall survival of 18.2 months in the STELLAR trial.

CAR-T cell therapy targeting the mesothelin protein is under active clinical investigation. Phase I results from Memorial Sloan Kettering Cancer Center showed a 72% objective response rate in 11 mesothelioma patients receiving intrapleural mesothelin-directed CAR-T cells combined with pembrolizumab.

See Treatment Options, Clinical Trials, and Mesothelioma Treatment Centers for comprehensive treatment information.

"The treatment landscape for mesothelioma has changed more in the last five years than in the previous two decades. Patients now have multiple FDA-approved options, and clinical trials are producing results that would have been unimaginable just ten years ago. We help families understand every option on the table."

— David Foster, Client Advocate, Danziger & De Llano

Who Is Most at Risk for Mesothelioma?

Mesothelioma primarily affects individuals with a history of asbestos exposure, though the disease's decades-long latency period means many patients are diagnosed long after their last exposure. Certain populations face disproportionately higher risk.

Occupational Exposure

Workers in asbestos-heavy industries carry the highest risk. The Occupational Exposure Index documents dozens of high-risk occupations, including construction tradespeople (insulation workers, plumbers, electricians, carpenters), shipyard workers, power plant and chemical plant personnel, steel mill and oil refinery workers, mining employees, and automotive mechanics who handled asbestos-containing brake pads and gaskets.

Military Veterans

Military veterans account for approximately 30% of all mesothelioma diagnoses in the United States, despite representing roughly 7% of the total population. The U.S. Navy has the highest rate of mesothelioma among all branches due to the extensive use of asbestos in shipbuilding and onboard insulation from the 1930s through the early 1980s. Navy veterans in high-exposure roles were found to be 6.47 times more likely to die from mesothelioma than the general population. All five military branches — Navy, Army, Air Force, Marine Corps, and Coast Guard — exposed service members to asbestos.

The PACT Act (2022) expanded VA coverage to recognize mesothelioma as a presumptive service-connected condition, qualifying veterans for an automatic 100% disability rating and monthly compensation of approximately $3,930 (2026 rate). See Veterans Benefits and Military Exposure Overview for complete eligibility information.

Secondary and Environmental Exposure

Secondary exposure through household contact with asbestos workers remains a significant risk pathway, disproportionately affecting women and children in worker households. Environmental exposure from naturally occurring asbestos deposits, contaminated vermiculite (such as the Libby, Montana disaster), and proximity to industrial operations also contributes to mesothelioma incidence.

Demographic Patterns

Mesothelioma affects men at roughly 3 to 4 times the rate of women, reflecting historical workforce demographics in asbestos-heavy industries. The median age at diagnosis is 72–75 years. Non-Hispanic White individuals account for approximately 90% of mesothelioma deaths, also reflecting historical industrial workforce composition.

"We see a consistent pattern in our cases: companies knew the risks of asbestos for decades and chose to keep using it. The workers who built our ships, insulated our buildings, and maintained our infrastructure are paying the price for those decisions."

— Rod De Llano, Esq., Founding Partner, Danziger & De Llano

What Compensation Is Available for Mesothelioma Victims?

Multiple compensation pathways exist for mesothelioma patients and their families. According to Danziger & De Llano case data, most eligible families qualify for compensation through more than one source simultaneously.

Asbestos Trust Funds

Approximately 60 active asbestos bankruptcy trust funds hold a combined estimated $30–$35 billion in remaining assets. These funds were established through Chapter 11 bankruptcy reorganizations by companies that manufactured or used asbestos products. Claimants can file with multiple trusts simultaneously based on their documented exposure history. Payment percentages vary by trust — from as low as 3.2% (ACandS Trust, as of 2024) to 100% (NARCO Trust) of scheduled claim values. See Asbestos Trust Funds, Johns Manville Trust, Owens Corning Trust, and Trust Fund Filing Guidance for specific trust information.

Mesothelioma Lawsuits

Mesothelioma lawsuits include personal injury claims (filed by the diagnosed patient) and wrongful death claims (filed by surviving family members). According to Mealey's Litigation Report: Asbestos, the average mesothelioma settlement ranges from $1 million to $1.4 million, while the average trial verdict reached $20.7 million in 2024 data. The vast majority of cases — approximately 95% — settle before trial, typically within 6 to 18 months from filing. Between 3,500 and 4,100 asbestos lawsuits are filed annually in U.S. courts. See Mesothelioma Claim Process and Settlement Values by State for detailed legal information.

VA Benefits

Veterans diagnosed with mesothelioma receive an automatic 100% disability rating from the Department of Veterans Affairs, qualifying them for the maximum monthly VA disability compensation — approximately $3,930 per month in 2026 for a single veteran. Surviving spouses may receive Dependency and Indemnity Compensation (DIC) at a base rate of $1,699 per month. The PACT Act (2022) designated mesothelioma as a presumptive service-connected condition, streamlining the claims process for veterans. See Veterans Benefits for complete details.

Social Security Disability

Mesothelioma qualifies for the Social Security Administration's Compassionate Allowances program, which expedites disability benefit processing. While standard SSDI claims typically take 3–5 months for an initial decision, Compassionate Allowance cases can be approved in as little as 10–14 days.

Workers' Compensation

Workers' compensation benefits are available in most states for occupationally exposed individuals. Filing a workers' compensation claim does not prevent a patient from also pursuing trust fund claims or civil lawsuits. See Immediate Financial Assistance for all available financial resources.

What Is the Statute of Limitations for Mesothelioma Claims?

Every state imposes a deadline — known as the statute of limitations — for filing mesothelioma-related legal claims. These deadlines vary significantly by state, ranging from 1 to 6 years depending on jurisdiction and claim type.

For mesothelioma cases, most states apply the discovery rule, meaning the statute of limitations clock begins at the time of diagnosis (or when the diagnosis reasonably should have been discovered), not at the time of the original asbestos exposure. This is particularly important given the disease's 20- to 50-year latency period.

Different deadlines typically apply to personal injury claims (filed by the patient) and wrongful death claims (filed by surviving family members after the patient's death). Some states also have special provisions for asbestos-related cases that may extend or modify standard filing deadlines. See Statute of Limitations by State for a complete state-by-state breakdown and Evidence Preservation for guidance on protecting your legal rights.

⏰ Statute of Limitations Warning: Filing deadlines for mesothelioma claims vary by state and claim type. Missing your deadline can permanently bar your right to compensation. Contact an experienced mesothelioma attorney as soon as possible after diagnosis. Call Danziger & De Llano at (866) 222-9990 for a free, confidential case review.

What Is the History of Asbestos and Mesothelioma?

The relationship between asbestos and human disease spans millennia, though the connection to mesothelioma specifically was not established until the mid-20th century.

Asbestos has been used by humans since at least 2,500 BCE, when ancient Greek and Roman civilizations valued the mineral for its fire-resistant properties. Commercial mining and industrial use expanded dramatically during the Industrial Revolution of the 1800s, and asbestos became ubiquitous in 20th-century construction, shipbuilding, manufacturing, and automotive industries.

The first medical warnings about asbestos-related disease emerged in the 1930s, when British factory inspectors documented elevated rates of lung disease among asbestos workers. Internal corporate documents — including the now-infamous Sumner Simpson letters and Saranac Laboratory studies — later revealed that major asbestos manufacturers were aware of the health dangers as early as the 1930s but actively suppressed this information to protect profits. See Corporate Asbestos Coverup for detailed documentation of this corporate concealment.

The definitive scientific link between asbestos exposure and mesothelioma was established in 1960 by Dr. J.C. Wagner and colleagues, who documented a cluster of mesothelioma cases in South African crocidolite asbestos miners. OSHA began implementing workplace asbestos regulations in the 1970s, setting the current permissible exposure limit (PEL) at 0.1 fibers per cubic centimeter. The first asbestos bankruptcy trust was established in the 1980s, and as of 2026, more than 60 active trusts continue to compensate victims. See Asbestos History Timeline and Johns Manville Corporate History for comprehensive historical information.

In March 2024, the EPA finalized a ban on chrysotile asbestos — the last commercially used form of the mineral in the United States — with phased compliance deadlines extending through 2036 for certain industrial applications.

Related Resources

Newly Diagnosed:

• Emergency Action Checklist — Immediate steps after a mesothelioma diagnosis
• Understanding Your Diagnosis — Guide to understanding your pathology report and staging

Medical Information:

• Treatment Options — Comprehensive treatment guide
• Clinical Trials — Current clinical trials accepting mesothelioma patients
• Mesothelioma Treatment Centers — Leading cancer centers specializing in mesothelioma
• Survival Statistics — Detailed survival data by type, stage, and cell type
• Mesothelioma Latency Period — Understanding the timeline from exposure to diagnosis

Legal & Compensation:

• Mesothelioma Claim Process — Step-by-step guide to filing a claim
• Asbestos Trust Funds — Complete guide to asbestos bankruptcy trust funds
• Statute of Limitations by State — Filing deadlines by state
• Settlement Values by State — Compensation data by jurisdiction
• Choosing a Mesothelioma Attorney — What to look for in legal representation

Exposure Information:

• Occupational Exposure Index — High-risk occupations and industries
• Shipyard Exposure Index — Naval and commercial shipyard exposure sites
• Secondary Exposure — Family member and household exposure risks
• Asbestos Products Database — Products known to contain asbestos

Veterans:

• Veterans Benefits — VA disability benefits and PACT Act coverage
• Military Exposure Overview — Asbestos exposure across military branches

🛡️ Free Mesothelioma Case Review If you or a loved one has been diagnosed with mesothelioma, the experienced attorneys at Danziger & De Llano can help you understand your legal options and pursue the compensation you deserve. 📞 Call (866) 222-9990 or visit dandell.com for a free, confidential consultation. 🔒 100% Confidential — No Obligation — Nationwide Representation